{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-268101","form_type":"8-K","ticker":"RGNX","cik":"0001590877","company_name":"REGENXBIO Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.849258+00:00","generated_at":"2026-05-16T23:42:02.008618+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"REGENXBIO reports Q3 2025 net loss $61.9M; pipeline advances with key milestones","bullets":["Net loss $61.9M ($1.20/sh) vs $59.6M ($1.17/sh) in Q3 2024; revenue $29.7M (+23% YoY).","Cash, equivalents $302M as of Sep 30, 2025; cash runway into early 2027.","RGX-202 Duchenne pivotal enrollment complete (n=30); topline early Q2 2026, BLA mid-2026.","RGX-121 (MPS II) PDUFA date Feb 8, 2026; CSF biomarker reduction >80% sustained at 1 year.","Sura-vec wet AMD pivotal enrollment complete (n=1,200+); topline Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-268101","json":"https://secwatch.observer/filing/0001193125-25-268101.json","markdown":"https://secwatch.observer/filing/0001193125-25-268101.md","text":"https://secwatch.observer/filing/0001193125-25-268101.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000119312525268101/0001193125-25-268101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000119312525268101/rgnx-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:42:02.008618+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}